The actual benefit of ERIVEDGE is substantial in the Marketing Authorisation indication.
Clinical Added Value
minor
Taking into account both the demonstration level (efficacy data limited to one non-comparative phase II study) and the absence of a valid alternative in the treatment of metastatic basal cell carcinoma and locally advanced basal cell carcinoma where surgery or radiotherapy is inappropriate, the Committee considers that ERIVEDGE provides a minor improvement in actual benefit (level IV) in the treatment strategy of these cancers.
Listen
